デフォルト表紙
市場調査レポート
商品コード
918179

がん性腹膜炎(PC)- 市場洞察、疫学、市場予測 2028年

Peritoneal Carcinomatosis (PC) Market Insights, Epidemiology and Market Forecast - 2028

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 116 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.56円
がん性腹膜炎(PC)- 市場洞察、疫学、市場予測 2028年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 116 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)におけるがん性腹膜炎(PC)の2017年の罹患数は9万1,416人、同年の市場規模は9億7,400万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のがん性腹膜炎(PC)市場について調査し、疾病の概要や現行の治療法、新薬および有望な候補薬のプロファイル、主要7カ国の市場動向、疫学的予測、市場規模、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 がん性腹膜炎(PC)市場の概要

  • がん性腹膜炎(PC)の分布(実数値)
  • がん性腹膜炎(PC)の分布(予測値)

第3章 疾病背景と概要:がん性腹膜炎(PC)

  • イントロダクション
  • 疾病の自然死
  • 病因の分類
  • 症状
  • 病態生理
  • スコアリングシステム
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国のがん性腹膜炎(PC)の総有病数
  • キーオピニオンリーダーの見解

第5章 仮定と理論的根拠

第6章 国別の疫学予測

  • 米国
    • 仮定と理論的根拠
    • 進行性がんにおけるがん性腹膜炎(PC)の総罹患数
    • 限局性がんにおけるがん性腹膜炎(PC)の罹患数
    • 再発性がんにおけるがん性腹膜炎(PC)の総罹患数
    • 限局性再発がんにおけるがん性腹膜炎(PC)の罹患数
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第7章 治療

第8章 アンメットニーズ

第8章 事例研究

第9章 新薬

  • GL-ONC1:Genelux Corporation
    • 製品概要
    • 製品開発動向
    • 臨床動向
    • 安全性と有効性
    • 製品プロファイル

第10章 その他の有望な候補薬

  • キークロスコンペティション
  • Radspherin:Oncoinvent AS
    • 製品概要
    • 製品開発動向
    • 臨床動向
    • 製品プロファイル

第11章 主要7カ国のがん性腹膜炎(PC)市場の分析

  • 主な調査結果
  • キーオピニオンリーダーの見解
  • 主要7カ国の市場規模
  • 主要7カ国の市場規模:治療薬別
  • 市場見通し

第12章 米国市場の見通し

  • 総市場規模
  • 市場規模:治療薬別

第13章 EU5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第14章 日本市場の見通し

  • 日本
    • 総市場規模
    • 市場規模:治療薬別

第15章 市場の成長要因

第16章 市場の障壁

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Key morphological features identified in metastatic carcinoma in ascites
  • Table 2: Comparison of imaging techniques
  • Table 3: Total Population of Peritoneal Carcinomatosis in the 7MM (2017-2028)
  • Table 4: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
  • Table 5: Incidence of PC in Site Specific Cancers in the US (2017-2028)
  • Table 6: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
  • Table 7: Incidence of PC by site-specific Recurrent Cases in the US (2017-2028)
  • Table 8: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
  • Table 9: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
  • Table 10: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
  • Table 11: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
  • Table 12: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
  • Table 13: Incidence of PC in Site Specific Cancers in France (2017-2028)
  • Table 14: Total Incidence of PC in Recurrent Cases in France (2017-2028)
  • Table 15: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
  • Table 16: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
  • Table 17: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
  • Table 18: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
  • Table 19: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
  • Table 20: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
  • Table 21: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
  • Table 22: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
  • Table 23: Incidence of PC by site-specific Recurrent Cases in Spain (2017-2028)
  • Table 24: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
  • Table 25: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
  • Table 26: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
  • Table 27: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
  • Table 28: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
  • Table 29: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
  • Table 30: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
  • Table 31: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)
  • Table 32: GL-ONC1, Clinical Trial Description, 2019
  • Table 33: Radspherin, Clinical Trial Description, 2019
  • Table 34: Market Size of Peritoneal Carcinomatosis Treatment in 7MMin USD Million (2017-2028)
  • Table 35: Market Size of Peritoneal Carcinomatosis by Therapies in 7MM in USD Million (2017-2028)
  • Table 36: Market Size of Peritoneal Carcinomatosis in the United States, USD Million (2017-2028)
  • Table 37: The US Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 38: Market Size of Peritoneal Carcinomatosis in Germany, USD Million (2017-2028)
  • Table 39: Germany Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 40: Market Size of Peritoneal Carcinomatosis in France, USD Million (2017-2028)
  • Table 41: France Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 42: Market Size of Peritoneal Carcinomatosis in Italy, USD Million (2017-2028)
  • Table 43: Italy Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 44: Market Size of Peritoneal Carcinomatosis in Spain, USD Million (2017-2028)
  • Table 45: Spain Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 46: Market Size of Peritoneal Carcinomatosis in the United Kingdom, USD Million (2017-2028)
  • Table 47: The UK Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Table 48: Market Size of Peritoneal Carcinomatosis in Japan, USD Million (2017-2028)
  • Table 49: Japan Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Anatomy of a Peritoneum
  • Figure 2: Types of Carcinomatosis
  • Figure 3: Ascites
  • Figure 4: Classification based on Primary and Secondary Tumors:
  • Figure 5: Classification based on Neoplastic and Non-neoplastic Conditions:
  • Figure 6: Tumor Entrapment Hypothesis in Gastric Cancer:
  • Figure 7: Symptoms of PC
  • Figure 8: The Peritoneal Metastatic Cascade:
  • Figure 9: The Peritoneal Cancer Index (PCI):
  • Figure 10: Diagnostic decision tree for identifying primary cancer which has metastatized to peritoneum
  • Figure 11: Total Diagnosed Patient Population of Peritoneal Carcinomatosiss in the 7MM (2017-2028)
  • Figure 12: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
  • Figure 13: Incidence of PC in Site Specific Cancers in the US (2017-2028)
  • Figure 14: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
  • Figure 15: Incidence of PC by site-specific Recurrent Case sin the US (2017-2028)
  • Figure 16: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
  • Figure 17: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
  • Figure 18: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
  • Figure 19: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
  • Figure 20: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
  • Figure 21: Incidence of PC in Site Specific Cancers in France (2017-2028)
  • Figure 22: Total Incidence of PC in Recurrent Cases in France (2017-2028)
  • Figure 23: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
  • Figure 24: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
  • Figure 25: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
  • Figure 26: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
  • Figure 27: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
  • Figure 28: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
  • Figure 29: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
  • Figure 30: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
  • Figure 31: Incidence of PC by site-specific Recurrent Case sin Spain (2017-2028)
  • Figure 32: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
  • Figure 33: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
  • Figure 34: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
  • Figure 35: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
  • Figure 36: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
  • Figure 37: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
  • Figure 38: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
  • Figure 39: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)
  • Figure 40: HIPEC Treatment
  • Figure 41: Treatment algorithm
  • Figure 42: Unmet Needs
  • Figure 43: Total Market Size of Peritoneal Carcinomatosis in 7MM in USD Million (2017-2028)
  • Figure 44: Market Size of Peritoneal Carcinomatosis by therapies in 7MM in USD Million (2017-2028)
  • Figure 45: Market Size of Peritoneal Carcinomatosis in the United States, USD Million (2017-2028)
  • Figure 46: The US Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 47: Market Size of Peritoneal Carcinomatosis in Germany, USD Million (2017-2028)
  • Figure 48: Germany Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 49: Market Size of Peritoneal Carcinomatosis in France, USD Million (2017-2028)
  • Figure 50: France Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 51: Market Size of Peritoneal Carcinomatosis in Italy, USD Million (2017-2028)
  • Figure 52: Italy Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 53: Market Size of Peritoneal Carcinomatosis in Spain, USD Million (2017-2028)
  • Figure 54: Spain Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 55: Market Size of Peritoneal Carcinomatosis in the United Kingdom, USD Million (2017-2028)
  • Figure 56: The UK Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 57: Market Size of Peritoneal Carcinomatosis in Japan, USD Million (2017-2028)
  • Figure 58: Japan Market Size of Peritoneal Carcinomatosis by Therapies in USD Million (2017-2028)
  • Figure 59: Market Drivers
  • Figure 60: Market Barriers
目次
Product Code: DIMI0760

DelveInsight's 'Peritoneal Carcinomatosis (PC) - Market Insights, Epidemiology and Market Forecast-202'8 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PCs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peritoneal Carcinomatosis (PC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Peritoneal Carcinomatosis (PC) - Disease Understanding and Treatment Algorithm

Peritoenal Carcinomatosis (PC) is a rare type of cancer that develops with the spread of gastrointestinal or gynecologic cancers which cause tumors to grow in the peritoneum. Patients often fail to notice the problem until PC advances. This happens mostly because the disease does not cause unusual symptoms, especially in its early stages. These factors lead to a significant amount of underestimation of the exact patient pool. An improved understanding of the global burden of PC, could have a significant effect on an early intervention and treatment.

The DelveInsight Peritoneal Carcinomatosis (PC) market report gives the thorough understanding of the Peritoneal Carcinomatosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Peritoneal Carcinomatosis in the US, Europe and Japan.

Peritoneal Carcinomatosis Epidemiology

The Peritoneal Carcinomatosis (PC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases) scenario of Peritoneal Carcinomatosis (PC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Peritoneal Carcinomatosis (PC) in 7 MM was found to be 91,416 in the year 2017.

Peritoneal Carcinomatosis Drug Chapters

This segment of the Peritoneal Carcinomatosis report encloses the detailed analysis of marketed drugs and late stage (Phase-II and Phase-I) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Despite the progress being made and the active research currently underway in peritoneal carcinomatosis, it remains a highly lethal condition. Oncolytic virotherapy is an emerging treatment modality for cancers of various origins and specifications. Oncolytic viruses (OV) are designed to selectively infect and damage cancerous tissues by intracellular replication and subsequent oncolysis without causing harm to normal tissues. As with most other types of cancer, there is growing interest in the genomic profiling of peritoneal carcinomatosis to gain insight into the biology of this form of metastatic disease. It is hoped that understanding the genetic mutations that drive cancer progression within the peritoneum will help to identify more specific targets for treatment.

Peritoneal Carcinomatosis Market Outlook

The Peritoneal Carcinomatosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of emerging therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Peritoneal Carcinomatosis in 7MM was found to be USD 974 Million in 2017, and is expected to increase during the course of the study period (2017-2028). The United States accounts for the largest market size of Peritoneal Carcinomatosis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Peritoneal Carcinomatosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Peritoneal Carcinomatosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Peritoneal Carcinomatosis Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Peritoneal Carcinomatosis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Peritoneal Carcinomatosismarket
  • Organize sales and marketing efforts by identifying the best opportunities for Peritoneal Carcinomatosis market
  • To understand the future market competition in the Peritoneal Carcinomatosis market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 24 Hours to deliver this kind of Report.

Table of Contents

1. Key Insights

2. Peritoneal Carcinomatosis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2017
  • 2.2. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Natural History of Peritoneal Carcinomatosis
  • 3.3. Classification of Causes of Peritoneal disease
  • 3.4. Symptoms of Peritoneal Carcinomatosis
  • 3.5. Pathophysiology of Peritoneal Carcinomatosis
  • 3.6. Scoring System
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Patient Population of Peritoneal Carcinomatosis
  • 4.3. KOL Views

5. Epidemiology - Assumptions and Rationale

6. Country Wise-Epidemiology of PC

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Incidence of PC in Advanced Stage Cancers
    • 6.1.3. Incidence of PC in Site Specific Cancers
    • 6.1.4. Total Incidence of PC in Recurrent Cases
    • 6.1.5. Incidence of PC by site-specific Recurrent Cases
  • 6.2. EU5 Countries
    • 6.2.1. Assumptions and Rationale
  • 6.3. Germany
    • 6.3.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.3.2. Incidence of PC in Site Specific Cancers
    • 6.3.3. Total Incidence of PC in Recurrent Cases
    • 6.3.4. Incidence of PC by site-specific Recurrent Cases
  • 6.4. France
    • 6.4.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.4.2. Incidence of PC in Site Specific Cancers
    • 6.4.3. Total Incidence of PC in Recurrent Cases
    • 6.4.4. Incidence of PC by site-specific Recurrent Cases
  • 6.5. Italy
    • 6.5.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.5.2. Incidence of PC in Site Specific Cancers
    • 6.5.3. Total Incidence of PC in Recurrent Cases
    • 6.5.4. Incidence of PC by site-specific Recurrent Cases
  • 6.6. Spain
    • 6.6.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.6.2. Incidence of PC in Site Specific Cancers
    • 6.6.3. Total Incidence of PC in Recurrent Cases
    • 6.6.4. Incidence of PC by site-specific Recurrent Cases
  • 6.7. United Kingdom
    • 6.7.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.7.2. Incidence of PC in Site Specific Cancers
    • 6.7.3. Total Incidence of PC in Recurrent Cases
    • 6.7.4. Incidence of PC by site-specific Recurrent Cases
  • 6.8. Japan
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Incidence of PC in Advanced Stage Cancers
    • 6.8.3. Incidence of PC in Site Specific Cancers
    • 6.8.4. Total Incidence of PC in Recurrent Cases
    • 6.8.5. Incidence of PC by site-specific Recurrent Cases

7. Treatment

8. Unmet Needs

9. Emerging Therapies

  • 9.1. GL-ONC1: Genelux Corporation
    • 9.1.1. Product Description
    • 9.1.2. Other Developmental Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and efficacy
    • 9.1.5. Product Profile

10. Other Promising Candidates

  • 10.1. Radspherin: Oncoinvent AS
    • 10.1.1. Product Description
    • 10.1.2. Product Development Activities
    • 10.1.3. Clinical development
      • 10.1.3.1. Clinical Trials Information
    • 10.1.4. Product Profile

11. Peritoneal Carcinomatosis: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. KOL Views
  • 11.3. Total Market Size of Peritoneal Carcinomatosis in 7MM
  • 11.4. Market Size of Peritoneal Carcinomatosis by Therapies in 7MM
  • 11.5. Market Outlook: 7MM

12. United States Market Size

  • 12.1. Total Market Size of Peritoneal Carcinomatosis
  • 12.2. Market Size of Peritoneal Caricnomatosis by Therapies

13. EU-5 Countries: Market Size

  • 13.1. Germany
    • 13.1.1. Total Market Size of Peritoneal Carcinomatosis
    • 13.1.2. Market Size of Peritoneal Caricnomatosis by Therapies
  • 13.2. France
    • 13.2.1. Total Market Size of Peritoneal Carcinomatosis
    • 13.2.2. Market Size of Peritoneal Caricnomatosis by Therapies
  • 13.3. Italy
    • 13.3.1. Surgical Total Market Size of Peritoneal Carcinomatosis
    • 13.3.2. Market Size of Peritoneal Caricnomatosis by Therapies
  • 13.4. Spain
    • 13.4.1. Total Market Size of Peritoneal Carcinomatosis
    • 13.4.2. Market Size of Peritoneal Caricnomatosis by Therapies
  • 13.5. The United Kingdom
    • 13.5.1. Total Market Size of Peritoneal Carcinomatosis
    • 13.5.2. Market Size of Peritoneal Caricnomatosis by Therapies

14. Japan market Size

    • 14.1.1. Total Market Size of Peritoneal Carcinomatosis
    • 14.1.2. Market Size of Peritoneal Caricnomatosis by Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight